In a phase III trial, one-year neratinib after trastuzumab-based adjuvant treatment for early-stage HER2 positive breast cancer reduced invasive disease-free survival events (116 vs 163 events; HR 0.73; p = 0.0083) without increasing risk of toxicity, which established its first approval [79]. This evidence concerns the gene ERBB2 and breast carcinoma.